Royalty Pharma Sub-Manager, LLC — 13F Holdings & Portfolio
CIK 2081668 · latest 13F-HR filed 2026-05-14
Royalty Pharma Sub-Manager, LLC manages $172.8M in 13F-reported U.S. long-equity assets across 4 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are CYTK (37.40%), BCAX (27.02%), BCRX (21.19%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 0 new positions, exited 0, added to 1, and trimmed 1.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$172.8M
Long-equity book
4
Distinct positions
2026-03-31
Filed 2026-05-14
+0 / −0 / ↑1 / ↓1
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | CYTOKINETICS, INC | CYTK | 23282W605 | $64.6M | 37.40% | 980,392 | SH |
| 2 | ZENAS BIOPHARMA, INC. | BCAX | 055477103 | $46.7M | 27.02% | 2,388,150 | SH |
| 3 | BIOCRYST PHARMACEUTICALS INC | BCRX | 09058V103 | $36.6M | 21.19% | 3,846,154 | SH |
| 4 | BIOHAVEN LTD | BHVN | G1110E107 | $24.8M | 14.38% | 2,936,507 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | $172.8M | 4 | 0002081668-26-000006 |
| 2025-12-31 | 2026-04-01 | $171.3M | 4 | 0002081668-26-000003 |